Deakin University
Browse
white-diagnosticroutesand-2018.pdf (817.33 kB)

Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; Findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP)

Download (817.33 kB)
Version 3 2024-06-18, 11:57
Version 2 2024-06-06, 10:35
Version 1 2019-01-31, 11:46
journal contribution
posted on 2024-06-18, 11:57 authored by D Weller, U Menon, A Zalounina Falborg, H Jensen, A Barisic, AK Knudsen, RJ Bergin, DH Brewster, V Cairnduff, AT Gavin, E Grunfeld, E Harland, M Lambe, RJ Law, Y Lin, M Malmberg, D Turner, RD Neal, Vicki WhiteVicki White, S Harrison, I Reguilon, P Vedsted
ObjectiveInternational differences in colorectal cancer (CRC) survival and stage at diagnosis have been reported previously. They may be linked to differences in time intervals and routes to diagnosis. The International Cancer Benchmarking Partnership Module 4 (ICBP M4) reports the first international comparison of routes to diagnosis for patients with CRC and the time intervals from symptom onset until the start of treatment. Data came from patients in 10 jurisdictions across six countries (Canada, the UK, Norway, Sweden, Denmark and Australia).DesignPatients with CRC were identified via cancer registries. Data on symptomatic and screened patients were collected; questionnaire data from patients’ primary care physicians and specialists, as well as information from treatment records or databases, supplemented patient data from the questionnaires. Routes to diagnosis and the key time intervals were described, as were between-jurisdiction differences in time intervals, using quantile regression.ParticipantsA total of 14 664 eligible patients with CRC diagnosed between 2013 and 2015 were identified, of which 2866 were included in the analyses.Primary and secondary outcome measuresInterval lengths in days (primary), reported patient symptoms (secondary).ResultsThe main route to diagnosis for patients was symptomatic presentation and the most commonly reported symptom was ‘bleeding/blood in stool’. The median intervals between jurisdictions ranged from: 21 to 49 days (patient); 0 to 12 days (primary care); 27 to 76 days (diagnostic); and 77 to 168 days (total, from first symptom to treatment start). Including screen-detected cases did not significantly alter the overall results.ConclusionICBP M4 demonstrates important differences in time intervals between 10 jurisdictions internationally. The differences may justify efforts to reduce intervals in some jurisdictions.

History

Journal

BMJ Open

Volume

8

Article number

ARTN e023870

Pagination

1 - 18

Location

England

Open access

  • Yes

ISSN

2044-6055

eISSN

2044-6055

Language

English

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2018, Author(s) (or their employer(s))

Issue

11

Publisher

BMJ PUBLISHING GROUP